Minotaur Therapeutics commercializes a new class of therapeutic based on the cow antibody scaffold. Cows have unique domains called "knobs" that are built within a traditional antibody. These knobs can be produced as independent fragments, which at 5 kDa are the smallest functional antibody fragments. These small knobs can bind recessed and challenging epitopes and, because of their small size, can penetrate tumors and other tissues more effectively than larger antibodies. The unique humanized cow antibody scaffold can also be used to stabilize unstable proteins, like cytokines. Minotaur's lead program is a stabilized IL-15 molecule for immuno-oncology applications.
Company Details
- Founded
- 2021
- Address
- 11011 Via Frontera,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Antibodies, Biotechnology, Cow antibodies, immuno-oncology, cytokine, cancer research, IL-15, knob domains, antibody fragment, multispecific antibodies, monoclonal antibody, long CDR3, immunology.
- HQ
- San Diego, CA
Minotaur Therapeutics Questions
Minotaur Therapeutics's website is http://www.minotaurtherapeutics.com
Minotaur Therapeutics's LinkedIn profile is https://www.linkedin.com/company/minotaur-therapeutics
Minotaur Therapeutics's industry is
Biotechnology Research
Minotaur Therapeutics's top competitors are
Mablytics, Inc.,
Redybio,
Galiana Technology,
Bio4t2,
Applied Biomedical Science Institute,
Theragene Pharmaceuticals,
Cell Biolabs, Inc.,
Camino Pharma, Llc,
Axiavita,
Levena Biopharma.
Minotaur Therapeutics's categories are Biotechnology Research
Minotaur Therapeutics's founding year is 2021
